Doripenem is an ultra-broad spectrum injectable antibiotic. It is a beta-lactam and belongs to the subgroup of carbapenems. It was launched by Shionogi Co. of Japan under the brand name Finibax in 2005, and is being marketed outside Japan by Johnson & Johnson. It is particularly active against Pseudomonas aeruginosa.
2 edits since May 19, 2008. Last edited Jul 13, 2008 by Carlo Banez (49).
This Compound Monograph is licensed under the GNU Free Documentation License and uses material from the Wikipedia article Doripenem. See this site's terms for details.